Holen Sie sich die Stockscreener-App
33.98
0.79%
0.225
Schlusskurs vom Vortag:
$33.75
Offen:
$33.85
24-Stunden-Volumen:
1.03M
Relative Volume:
0.26
Marktkapitalisierung:
$14.62B
Einnahmen:
$2.27B
Nettoeinkommen (Verlust:
$1.15B
KGV:
13.32
EPS:
2.55
Netto-Cashflow:
$2.80B
1W Leistung:
+1.81%
1M Leistung:
+0.96%
6M Leistung:
+23.02%
1J Leistung:
+12.33%
1-Tages-Spanne:
$33.63
$34.14
1-Wochen-Bereich:
$33.15
$34.14
52-Wochen-Spanne:
$24.05
$34.20
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
33.99 | 14.62B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.76 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.42 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
287.76 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
606.29 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
251.75 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
15 Best Defensive Stocks Amid Market Volatility - Insider Monkey
Sciencast Management LP Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Royal London Asset Management Ltd. - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by HighTower Advisors LLC - MarketBeat
Fox Run Management L.L.C. Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Thrivent Financial for Lutherans Raises Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Twin Tree Management LP - MarketBeat
Horizon Kinetics Asset Management LLC Purchases 90,380 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Swiss National Bank Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Koss Olinger Consulting LLC Invests $269,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks - Barchart
Raymond James Financial Inc. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How Do Investors Really Feel About Royalty Pharma? - Benzinga
Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - Simply Wall St
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Tredje AP fonden - MarketBeat
Atria Investments Inc Sells 20,550 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Jupiter Asset Management Ltd. Invests $4.95 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
AGF Management Ltd. Buys Shares of 98,512 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Wealthfront Advisers LLC Buys 178,173 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Amundi Trims Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
River Road Asset Management LLC Trims Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Machina Capital S.A.S. Sells 12,740 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Proficio Capital Partners LLC Makes New $786,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Trims Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Victory Capital Management Inc. Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Menlo Advisors LLC - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by New South Capital Management Inc. - MarketBeat
Proficio Capital Partners LLC Invests $786,000 in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Metis Global Partners LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Plato Investment Management Ltd - MarketBeat
Truist Financial Corp Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Cuts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Principal Financial Group Inc. Has $513,000 Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Torray Investment Partners LLC Has $17.45 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
SBI Securities Co. Ltd. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):